# Modern drug delivery system 2.

## Prof. emer. Dr. Hódi Klára

PTE-Institute of Pharmaceutical Technology and Biopharmacy, Pécs, 17/April 2018.



**Multiparticulate dosage forms Gastroretentive preparation** Cronotherapy/cronotechnology/pulsatile dosage forms **Colon therapy Self-controlled systems Implants Pediatrics preparations Excipients** Halving/breaking problems **Other innovative solutions Targeted drug delivery systems** 

## Multiparticulate dosage forms

These consist of many mini-depots (pellets or microencapsulated crystals) in a capsule or a tablet, or minitablets in a capsule.

These mini-depots are dispersed and distributed throughout the GI tract when the capsule or tablet disintegrates.

The tablet may be divided without loss of the depot effect.







http://www.acino-pharma.com 3

### **Minitablets**





#### **Multiple-tip tooling**

### Advantages:

- Easy to swallow
- Good alternative to pellets
- Direct compression is possible



- Coating is possible (in a perforated coating pan or a fluid bed apparatus)
- Complex release profiles is possible (i.e. initial and maintenance dose in one capsule)
- Several chemically incompatible drugs pressed into minitablets, coated and combined in one single capsule
- May offer a solution for pediatrics

#### **Disadvantage:** The punches can easily break

## **Minitablets**



#### **Controlled release preparation**



### "Reservoir" systems"

#### **MUPS = Multiple Unit Pellet System**



100 m 100 m



Müller, R.H., Hildebrand, G.E.: Pharmazeutische Technologie: Moderne Arzneiformen, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 1998

#### Matrix pellet with pH-dependent coating



Cross-section of the double-coated pellet (SEM). Magn.: 50x

Atenolol could not dissolve from the double-coated pellets in gastric juice because the protective layer closed the pores of the core and did not allow the migration of any component in the outer layer.



Cross-section of the double-coated pellet (SEM). Magn.: 400x 1: protective layer; 2: functional layer



Dissolution profiles of Atenolol from the single-coated and double-coated pellets

E.I. Hamedelniel, J. Bajdik, T.Sovány, K. Pintye-Hódi: Delayed release matrix pellet preparation containing an alkalizing pore-former agent, Chem. Eng. Res. Des. 2011, 89, 1006-1010

#### In vitro testing of coated pellets

## Pellets coated with pH-independent polymer

#### In vitro testing of uncoated pellets









#### In vivo testing of coated pellets in rabbits



Muskó Zs., et al.: Study of in vitro and in vivo dissolution of theophylline from film-coated pellets Eur. J. Pharm. Biopharm. 2001, 51, 143-146

#### Some information of the characteritics





Single unit dose	Multiparticulate unit dose
<ul> <li>Transport dependent on gastric emptying</li> </ul>	Transport virtually independent of gastric emptying
<ul> <li>Transport strongly influenced by intestinal motility and transit time of food</li> <li>Varying rate and extent of bioavailability</li> </ul>	<ul> <li>Transport only moderately affected by intestinal motility and transit time of food Reproducible bioavailability</li> </ul>
Risk of accumulation of doses Risk of high local drug concentrations Risk of local irritations	No risk of accumulation of doses and its consequences
Tablets non-dividable	Tablets dividable

# Gastroretentive preparations

**Gastroretentive preparations** can prolong the residence time in the stomach for hours. They are perfect for the therapy of proximal region of the small intestine.

#### Application

- extended local effect (antacids, ulcer)
- improved bioavailability because of the most proper site of absorption of an API API's with narrow absorption vindow: aciklovir, atenolol, diltiazem, furosemide, itrakonazol, levodopa, riboflavin, etc.
- avoidance of the other parts of the GI tract (amoxicillin trihydrate colon flora)
- stability is suitable in intestine: captopril
- protection of the API (ranitidine-HCl and metronidazole)







Mean plasma concentration of RF dosed after a light meal with an IR formulation (blue) or a GRDF (purple).

## Floating systems



#### **Madopar HBS**

Matrix pellet: methyl-hydroxy-propyl-cellulose hydrogenized vegetable oil etc.





Unfolded systems



## Systems based on gase forming









The gastric floating system involved <u>sodium bicarbonate as a gas-forming agent</u> dispersed in the hydrogel matrix. On reacting <u>with hydrochloric acid</u>, the bicarbonate ion is converted to <u>carbon dioxide</u> in the form bubbles on the surface of the tablets, which caused the tablets to float in the fluid for more than 4 h *in vitro*.<sup>15</sup> Patients keep seat!

## Chronobiology

### Circadian rhythm of human body (day cycle)



The circadian rhythm is determined by exogenous and endogenous processes.

The cycles are regulated by the hypothalamic nuclei (the suprachiasmatic neurons, SCN).

The rhythm of day and night is detected by light-sensitive cells of the retina.

The pineal gland get a signal for the emptying of "darkness hormone" melatonine.

### Chronotherapy



### **Chronopharmacotherapy diseases**

- Asthmatic attack during early morning
- *Heart attacks* in the middle of the night
- Morning *stiffness* in arthritis
- *Peptic ulcer* during afternoon and night







Chronotechnology

Possibility of regulation

Lag time: decrease increase

Speed of the drug release: decrease increase

Duration of drug release: decrease increase

Kinetic of the drug release: zero order first order

Design of drug release: site controlled time controlled



## **Technological possibility**

#### a.) controlled systems

- time (delayed release)
- site ("local release") pH, enzymes, bacterium

Disadvantage: rigidity

#### b.) systems that are sensitive to biologic signals

- stimuli-sensitive polymers (pH, temperature...)
- self-control systems

Disadvantage: "high quality" technology, expensive

## Diffucaps® chronotherapeutic system

- Propranolol (InnoPran XL<sup>™</sup>)
- Multipartculate system
- After the administration at pm. 22 o'clock, c<sub>max</sub> will be at 10 o'clock am.



## Diffucaps® chronotherapeutic system



# **Colon therapy**

Anatomy of colon



## **Specific environment**

- low amount of dissolution medium,
- pH 6,8-7,8
- no digestion,
- intestinal flora,
- water reabsorption.

Preparations must to reach the colon without no damage.

## **Advantages of colon therapy**

Target therapy Decrease the dose Decrease the side effect Increase the bioavailability

## **Deseases in colon**

	Desease	APIs	
Local action	Inflamation in colon Crohn desease Chronic pancreatitis	Hydrocortisone, prednisolone, sulfasalazine, olsalazine, mesalazine, balsalazine	
	Removal the pancreas, cistic fibrosis, cancer in colon	Peptic enzimes, 5-fluorouracyl	
Systematic action	Avoiding the irritation in gastric, Avoiding the "first pass" effect, Administration some peptids, Administration some vaccines	NSAIDS Steroids Insulin Typhoid	



lesions

#### **Colon inflamation**



#### **Colitis ulcerosa**

Continuous



## **Cancer in colon**



#### **Malignant tumour**



But a tiny percentage of these polyps keep growing, sometimes for 10 years or more. Various genetic mutations can transform them into cancerous tumors



As these tumors grow larger, they gather more mutations and begin to burrow deeper and deeper into the muscle wall that surrounds the colon



Once the cancer invades the blood and lymph systems, malignant cells can break off and spread to other organs, such as tho liver, lungs and stomach









CH<sub>2</sub>  $CH_2$ CHCONH<sub>2</sub> CHOH C = 0C = 0 $CH_2$ 2 NH NH  $CH_2$ (CH<sub>2</sub>)<sub>2</sub> C = 0NH OH NH C = 0Fructose N N COOH

- I. **Sulfasalazine**
- II. Olsalazine
- 5-Amino-salicylic acid III.

(diazoreductase enzyme)

#### **Polymer-prodrug**

OH

Polymer molecule: poly-sulfonamido- 31 etilene

 $CH_2$ 

CH<sub>3</sub>

(II)



### **Enzyme degradation**





## **Ester bonds**













#### **Degradation by enzymes**

The natural polysaccharids (pectine, xylane, chitosane etc.) are not digestible in stomach or in small intestine, bat they degradate in the colon by the bacteriums, which are in the colon.



#### Volume change of hydrophil gels







Effect	Hidrogel	Mechanism		
рН	Acid, base hidrogel	pH change — swelling — API release		
lonic strength	lonic hidrogel	The ion concentration in the matrix is alerted by the ion strength — swelling — API release		
Chemical	Electron-acceptor hidrogels	Complex formation (aceptor-donor molecula) — swelling — API release		
Ensim- substrate	Ensim containing hidrogel	The substrate activates the enzyme — enzymatic transformation — swelling — API release		

Effect	Hidrogel	Mechanism
Temperature	Thermal sensitive hidrogel	Temperature change — danger in the polymer-polymer and water-polymer interaction — swelling — API release
Electric field	Polyelectrolyte hidrogels	It can alert the — charge of the membrane — electrophoretic release of the API — wetting — liberation of the API
Ultrasound	Ethylene-vinyl alcohol	The US can — increase the temperature — enhanced dissolution rate

We can use these effects. E.g. such polymer is chosen, which phase transition temperature is around 40 °C. In lower temperature these polymers are in dissolved phase, above 40 °C in aggregated phase. Given material accumulated around tumour because of increased temperature of tumour cells.

## Some other possibility

## **Accu-Break Pharmaceuticals Inc.**

Caterpillar-tablet



#### **Multidose tablet**



#### Incompatible drugs





#### *"LEGO" tablets* (*Dome matrix module*)







Moodley K, Pillay V, Choonara YE, du Toit LC, Ndesendo VM, Kumar P, Cooppan S, Bawa P : Oral Drug Delivery Systems Comprising Altered Geometric Configurations for Controlled Drug Delivery, Int J Mol Sci (2011)

## **Tablets with sensors**

Otsuka Pharmaceutical Co., Ltd

Proteus Digital Health



(schizophrenia, bipolar disorder, depression)

Parts of the administration:



sensitive patch (to put on the thorax

the information transmit to a mobil

2 mg

10 mg

20 mg





#### **Osmotic systems**

#### **Subcutaneous application**











Norplant



45

### **Biodegradable rod after implantation**

#### **Erodable implants**



#### 9 weeks

#### **16 weeks**

#### Local "implant" in dental administration

#### Local depot





Drug release: 18 µg/h, 7 day

48

# **Pediatrics preparations**

## **Pediatrics preparations**

**FDDF** tablets **ODT** preparations **Mucoadhesive films** "Suckers"



## STATE REAL ANTIALLERGIKUM tenin Sen





300 Lutschtabletten ¥Aventis

#### **Electronic tongue**



Breitkreutz J.: Pre-clinical Research, (Pharmacology and Formulations), PRIOMEDCHILD Conference 50 London, November 6-7, 2008

## **SIP technology**



www.bbc.co.uk/2/hi/health

#### Clarosip (klaritromicin) (Grünenthal GmbH)





Granules or pellets in sucker



Breitkreutz J.: Pre-clinical Research, (Pharmacology and Formulations), PRIOMEDCHILD Conference, 51 London November 6-7, 2008

## Excipients

## **Excipients**

### **Excipients for influence of drug release**

Hidrogels:poly hidroxy(unsoluble)cross linked pcross linked ppoly ethylenepoly acrylam	ethyl metacrylate (PHEMA poly vinyl alcohol (PVA) poly vinyl pyrrolidone (PV e oxide (PEO ide (PA)	A) PP)		
		Soluble polymers	: poly ethylen poly vinyl al poly vinyl py hidroxyprop	a glycol (PEG) Icohol (PVA) yrrolidone (PVPP) oil methylcellulose (HPMC)
<b>Biodegredable polimers:</b>	polylactic acid (PLA)			
	polyglycol acid (PGA) polycapro lacton (PCL) polyanhydrids polyorthoesters	<u>Non biodegredab</u>	<u>le polymers</u> :	poly vinyl acetate (PVA) poly dimethyl syloxane (PDS) poly ether urethane (PEU) poly vinyl chloride (PVC)
				cellulose acetate (CA) ethylcellulose (EC)
Mucoadhesive polymers: carboxy methylcellulose sodium         poly acryl acid         tragacantha         methylcellulose         pectin		odium (CMCNa)	Natural poly	saccharids: xanthan gum guar gum
				53



**Unorganic water soluble compounds:** 

### MgSO<sub>4</sub>, NaCl, KCl, Na<sub>2</sub>SO<sub>4</sub>, NaHCO<sub>3</sub>

#### Organic polymers: CMCNa, HPMC, hydroxy-ethyl- methylcell., MC, PEO, PVP

## To break or not to break? When is it possible?



### ... if the mechanism of drug release is not influenced.



### Multiparticulate systems



Pl. Betaloc ZOK, Metoprolol Z

... breaking is possible, but the pulverize and mastication is vorbidden!

# To break or not to break?

**Practical tips** 

## No breaking



- buccal and sublingual tabletsk
- bélben oldódó bevonatú tabletták
- sustained release or slow release non multiparticulate tablets (SR, LA, CR, SA, TD, TR, XL)
- coated tablets
- layered tablets
- multiparticulate tablets prepared from pellets with different

#### drug contents

- matrix tablets
- OROS tablets
- gastroretentive preparations



### **Breaking is possible**

- gastric soluble coated and sugar coated tablets
- chewing tablets
- some mucoadhesive preparations

# Is it possible to open or chew the capsules?

#### **Open is possible**

- content is powder mix with liquid (incompatibility!)
  - dust on the surface of food (pl. ampicillin, doxycyclin)

#### No open and no chewing:

- sustained release capsules (with pellets, crystals or granules)
- OROS capsuls

#### No chewing:

- modified release capsules
- coated capsules
- content is enterosolvent pellets

Chemotherapy

Side effects of chemotherapy

methotrexate - liver and kidney damage, loss of hair, doxorubicin - myocardial damages, vincristine - peripheral nerve injury, alopecia, daunorubicin- muscle and bone marrow damage, cytarabine - bone marrow and intestinal damage

**Important:** Only the liberated substance can be absorbed in the target cell<sup>51</sup>

#### Passive targeting

Passive tumor deposition by non targeted is accomplished by extravasation from leaky vessels adjacent to the tumor and retention of nanoparticles at the tumor site due to slow clearance.

Cancer tissues are different of healthy tissues:

- enhanced vascular permeability.
- decreased lymphatic flow.



The residence time of nanoparticles increase in the tumor.

## Liposome

## **Doxil**<sup>R</sup>

- natural polyphospholipids
- the heads of hydrophil phosphates stand outwards respectively inward



Application of nanoparticles in nuclear medicine

András Polyák PhD thesis, 2011, SE <sup>99m</sup>Tc-tracer doxorubicin



magnetic liposomes

1st step: collection of the particles in the magnetic field

2nd step: liberation of the API

Active targeting

Three levels of active targeting:

#### 1. First order targeting - organ targeting.

DDS <u>release the drug</u> only in a specific predetermined target site, <u>organ or tissue</u> including lymphatics, peritoneal cavity, plural cavity, cerebral ventricles, eyes, joints, etc.

#### 2. Second order targeting - cellular targeting.

DDS particles <u>release the drug</u> to a particular <u>cell within an organ or tissue</u>. Selective delivery of drugs as tumour cells and not to the normal cells(e.g. selective drug delivery to kupffer cells in the liver). Usually an antibody is attached to the surface of a DDS particle, which able to specifically recognize and to bound to a specific antigen on a cell surface.

#### 3. Third order - subcellular targeting.

It is defined as drug delivery specifically to the intracellular site of targeted cells (eg. receptor based ligand mediated entry of a drug complex into a cell by endocytosis.) *For example: gen delivery.* <sup>65</sup>



# **Externaly controllable systems**

## **Externaly controllable systems**

#### Patient Controlled Analgesia (PCA)





The patient can administers the pain relief. The infusion is programmable by the prescriber.





### Thank you for your attention!



#### **Artifact during preparation for TEM**

### Externally controlled DDSs

#### iPill diagnostic

#### iPill drug therapy





